PTGX PROTAGONIST THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, PROTAGONIST THERAPEUTICS INC reported revenue of $213M (up 3749.2% from a year earlier), net income of $163M and diluted EPS of $2.29; over the last four quarters revenue was $282M and net income $82.9M; for the fiscal year ended December 2025 revenue was $46.0M, down 89.4% on the year before.

PTGX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $46.0M, gross profit n/a, operating income −$158M, net income −$130M (margin -282.8%), EPS −$2.05
• Fiscal year ended Dec 2024: revenue $434M, gross profit n/a, operating income $253M, net income $275M (margin 63.3%), EPS $4.23
• Fiscal year ended Dec 2023: revenue $60.0M, gross profit n/a, operating income −$93.7M, net income −$79.0M (margin -131.6%), EPS −$1.39
• Fiscal year ended Dec 2022: revenue $26.6M, gross profit n/a, operating income −$131M, net income −$127M (margin -479.3%), EPS −$2.60
• Fiscal year ended Dec 2021: revenue $27.4M, gross profit n/a, operating income −$126M, net income −$126M (margin -458.9%), EPS −$2.71

PTGX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $213M (up 3749.2% year over year), net income $163M, EPS $2.29
• Quarter ended Mar 31, 2026: revenue $56.4M (up 99.0% year over year), net income $3.78M, EPS $0.05
• Quarter ended Dec 31, 2025 (from the annual report): revenue $7.44M (down 95.6% year over year), net income −$44.4M, EPS −$0.69
• Quarter ended Sep 30, 2025: revenue $4.71M (up 0.8% year over year), net income −$39.3M, EPS −$0.62
• Quarter ended Jun 30, 2025: revenue $5.55M (up 33.1% year over year), net income −$34.8M, EPS −$0.55
• Quarter ended Mar 31, 2025: revenue $28.3M (down 88.9% year over year), net income −$11.7M, EPS −$0.19
• Quarter ended Dec 31, 2024 (from the annual report): revenue $171M (up 184.4% year over year), net income $132M, EPS $2.01
• Quarter ended Sep 30, 2024: revenue $4.68M, net income −$33.2M, EPS −$0.54
• Quarter ended Jun 30, 2024: revenue $4.17M, net income −$30.6M, EPS −$0.50
• Quarter ended Mar 31, 2024: revenue $255M, net income $207M, EPS $3.26
• Quarter ended Dec 31, 2023 (from the annual report): revenue $60.0M, net income $27.3M, EPS $0.54
• Quarter ended Sep 30, 2023: revenue $0, net income −$34.1M, EPS −$0.58
• Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$38.5M, EPS −$0.68
• Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$33.7M, EPS −$0.67
• Quarter ended Dec 31, 2022 (from the annual report): revenue $0 (down 100.0% year over year), net income −$34.2M, EPS −$0.69
• Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$31.2M, EPS −$0.64
• Quarter ended Jun 30, 2022: revenue $859K (down 62.1% year over year), net income −$41.0M, EPS −$0.84
• Quarter ended Mar 31, 2022: revenue $25.7M (up 315.6% year over year), net income −$20.9M, EPS −$0.43
• Quarter ended Dec 31, 2021 (from the annual report): revenue $8.62M, net income −$36.9M, EPS −$0.78
• Quarter ended Sep 30, 2021: revenue $10.3M, net income −$33.8M, EPS −$0.70

PTGX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $57.7M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow $184M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$70.2M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$108M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$108M, share buybacks n/a

PTGX balance sheet

• Jun 30, 2026: cash $420M, total assets $886M, total liabilities $44.0M, shareholders' equity $842M
• Mar 31, 2026: cash $194M, total assets $697M, total liabilities $42.0M, shareholders' equity $655M
• Dec 31, 2025: cash $128M, total assets $668M, total liabilities $53.5M, shareholders' equity $615M
• Sep 30, 2025: cash $114M, total assets $702M, total liabilities $56.3M, shareholders' equity $645M
• Jun 30, 2025: cash $169M, total assets $718M, total liabilities $50.0M, shareholders' equity $668M
• Mar 31, 2025: cash $140M, total assets $742M, total liabilities $53.1M, shareholders' equity $689M
• Dec 31, 2024: cash $97.2M, total assets $745M, total liabilities $69.4M, shareholders' equity $675M
• Sep 30, 2024: cash $131M, total assets $604M, total liabilities $71.9M, shareholders' equity $532M

What is PTGX's revenue?

PROTAGONIST THERAPEUTICS INC reported $282M of revenue over its last four quarters, through June 30, 2026.

Is PTGX profitable?

Yes. PROTAGONIST THERAPEUTICS INC earned $82.9M over the last four quarters.

What is PTGX's EPS?

Diluted earnings per share over the last four quarters were $1.03; $2.29 in the latest quarter.

PTGX ownership and insider trades · All stocks